Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) surged 9.20% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results and raised full-year guidance. The biopharmaceutical company, focused on developing and commercializing novel therapies for rare liver diseases, reported better-than-expected earnings and revenue growth, driven by strong sales of its key products.

Mirum reported a quarterly adjusted loss of $0.12 per share, significantly beating the analyst consensus estimate of a $0.34 loss. This marks a substantial improvement from the $0.52 loss per share in the same quarter last year. The company's total revenue for Q2 2025 reached $127.79 million, an impressive 64.1% increase year-over-year, surpassing analysts' expectations of $108.17 million. Global net product sales were $127.8 million, with LIVMARLI contributing $88.2 million, representing an 87% increase compared to Q2 2024.

In light of its strong commercial performance, Mirum has raised its full-year 2025 revenue guidance to between $490 million and $510 million. The company also highlighted significant progress in its product pipeline, including the VISTAS study of volixibat in primary sclerosing cholangitis, which is set to complete enrollment this quarter. Additionally, Mirum reported a solid financial position with $321.7 million in unrestricted cash, cash equivalents, and investments as of June 30, 2025. The combination of robust financial results, raised guidance, and advancing pipeline appears to have fueled investor optimism, leading to the significant after-hours stock price increase.